Your browser doesn't support javascript.
loading
Ramucirumab in second­line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation.
Kimura, Keisuke; Katata, Yosuke; Umeda, Yuzo; Tanaka, Takehiro; Yano, Shuya; Yoshida, Kazuhiro; Fujiwara, Toshiyoshi; Mori, Yoshiko; Yamada, Takeshi; Nagasaka, Takeshi.
Afiliación
  • Kimura K; Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Katata Y; Department of Clinical Oncology, Kawasaki Medical School Hospital, Kurashiki, Okayama 701-0192, Japan.
  • Umeda Y; Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Tanaka T; Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
  • Yano S; Department of Clinical Oncology, Kawasaki Medical School Hospital, Kurashiki, Okayama 701-0192, Japan.
  • Yoshida K; Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Fujiwara T; Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Mori Y; Department of Gastroenterological Surgery, Okayama University Hospital, Okayama 700-8558, Japan.
  • Yamada T; Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan.
  • Nagasaka T; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan.
Oncol Lett ; 28(3): 439, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39081965
ABSTRACT
The present study investigated the role of ramucirumab (RAM) in treating liver metastases (LMs) as a second-line or salvage treatment in patients with advanced CRC. Of the 36 patients, 21 (58%) received RAM plus folinic acid, fluorouracil and irinotecan (FOLFIRI) as second-line treatment, whereas 15 (42%) received it in a salvage setting. The median overall survival time was 23 months [95% confidence interval (CI), 12-34 months] for those in the second-line treatment group and 8 months (95% CI, 5-19 months) for those in the salvage treatment group. Of the 36 patients, 14 (39%) underwent surgical resection of LMs during chemotherapy. A total of 6 patients underwent surgical resection for LMs for the first time during second-line RAM plus FOLFIRI (RAM-LM); of the remaining 8 patients, 6 underwent resection of LMs during first-line bevacizumab (BEV)-based chemotherapy (BEV-LM). Immunohistochemical analysis of CD42b showed that the platelet aggregation score (CD42b score), which ranges from 0 (absence of deposition) to 3 (presence of linear deposition), tended to decrease with the increasing duration of treatment with both RAM and BEV. Although there was no significant difference in the mean duration of anti-VEGF antibody treatment between the BEV-LM and RAM-LM groups, the median CD42b score was higher in the RAM-LM group (median CD42b score, 3; range, 0-3) compared with that in the BEV-LM group (median CD42b score, 1; range, 0-3; P=0.01), suggesting that RAM induces a different degree of platelet aggregation in liver sinusoids compared to BEV.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Lett Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Lett Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia